Curium completed the acquisition of Belgian radiopharmaceutical company Abscint SA on Monday [1].
The deal expands Curium's oncology radiodiagnostic footprint by adding specialized tools for detecting breast and gastric cancers. This move strengthens the company's ability to provide precise imaging for patients with HER2-positive tumors.
Based in Liège, Belgium, Abscint SA brings a key asset to the Curium portfolio: the investigational PET radiodiagnostic tracer ABS-011 [1]. This gallium-68-labeled tracer is currently in Phase 2b trials [1]. The tracer specifically targets HER2, a protein that promotes cell growth in certain types of cancer.
Curium, which maintains corporate offices in Boston, U.S., aims to integrate this technology into its global pipeline [1]. By acquiring the Belgian firm, Curium gains immediate access to advanced PET imaging research that could streamline how clinicians identify and monitor HER2-expressing malignancies.
The acquisition allows Curium to scale the development of ABS-011 using its existing global infrastructure [1]. The company intends to use the tracer to improve diagnostic accuracy in oncology, a critical step in tailoring personalized treatment plans for cancer patients.
Radiopharmaceuticals combine radioactive isotopes with targeting molecules to visualize biological processes in the body. The addition of Abscint SA's technology represents a strategic pivot toward more specialized molecular imaging in the oncology sector [1].
“Curium completed the acquisition of Belgian radiopharmaceutical company Abscint SA on Monday.”
This acquisition signals a growing industry trend toward 'theranostics,' where diagnostic tracers like ABS-011 are used to identify specific biomarkers before administering targeted therapy. By securing a Phase 2b asset, Curium reduces the risk of early-stage development while positioning itself to dominate the HER2-imaging market for breast and gastric cancers.
